On April 14th, The 22nd Annual Conference of Chinese Biologics (CBioPC20) was co-sponsored by China Vaccine Industry Association, Chinese Pharmaceutical Society Biologics and Quality Research Committee, Chinese Preventive Medicine Association Biologics Branch, Chinese Preventive Medicine Association Vaccine and Immunization Branch, Chinese Pharmaceutical Biotechnology Association Vaccine Committee, and Chinese Microbiology Society Biologics Committee 22) Successfully concluded in Zhuhai.

This annual meeting lays equal emphasis on multiple disciplines and has a strong academic atmosphere, which not only broadens the research ideas of researchers, but also provides new trends in the industry for production enterprises, and also builds a good platform for exchanges and cooperation between research units and application units, which is highly praised by all parties, and the conference has achieved a complete success.

The conference includes "Vaccine Development and Quality Forum", "Recombinant Therapeutic Biological Products Forum", "Cell Therapy and Gene Therapy Forum", "Vaccination Summit Forum", "Blood Products Forum", "Biopharmaceutical Engineering and Technology Forum", "Data-driven Biomedical Research and Development Strategy Forum", "the Fourth China Vaccine Innovation Forum and Vaccine Clinical Research Sub-Forum", "The Fourth China Vaccine Innovation Forum". There were 14 sub-sessions, including the Vaccine Immunoassay Technology Forum and the Biopharmaceutical Equipment and Materials Innovation Forum. The venue reports are colorful and full of dry goods.

>>>>>Venue review

The conference set up a main sub-venue around the cutting-edge technology of biomedicine, and invited the most authoritative experts in the field of biomedicine to exchange academic reports.

The opening ceremony of the conference was presided over by Feng Duojia, president of China Vaccine Industry Association. After the opening ceremony, the keynote report of the conference was presided over by academician Wang Junzhi of the Chinese Academy of Engineering and researcher Zhang Yuntao of China Biotechnology Co., LTD.

>>>>>exhibition hall

The conference invited nearly 100 biomedical enterprises to gather together, effectively promoting the effective docking of finance and industry, scientific research and application, and government and enterprises, driving the coordinated development of the biomedical industry, and efficiently guiding the concentration of technology, talent, capital and other resources to the biomedical field.

This annual meeting focused on the innovation and development of biological products, invited the most authoritative and influential scientists, experts and other elite representatives in the field of medicine in China, organized nearly 200 academic reports, cahhied out a variety of academic exchanges, industrial exchanges and industry exchange activities, and discussed the latest technological achievements in the field of biomedicine.

As a leading enterprise in China's biomedicine industry, Zhongyuan company participated in the exhibition jointly in the form of double booth and double platform for the first time. Zhongyuan Bio aims to "promote the life science business to serve the biomedical industry" as its mission, and BiO Lianke aims to "become a global special biological products supply chain service platform" as its vision, relying on its own perfect import and export logistics, rich import agent resources, to provide quality services for domestic biopharmaceutical customers and foreign suppliers. Committed to the development of China's biomedical industry.

Zhongyuan Company thanks for the support and recognition of our peers and friends.

At this point, the 22nd China Biologics Annual Conference has come to a successful end in Zhuhai, looking forward to our next meeting!